PMID- 26191178
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 5
DP  - 2015
TI  - Bortezomib inhibits bone marrow-derived dendritic cells.
PG  - 4857-62
AB  - Graft versus-host disease (GVHD) severely limits the application of allogeneic 
      hematopoietic stem cell transplantation (allo-HSCT) in treating leukemia. 
      Dendritic cells (DCs) are critical for the development. Here, we examined the 
      effect of proteasome inhibitor Bortezomib on DCs in vitro. Primary cultured mouse 
      DCs were treated with Bortezomib and their proliferation was observed. The 
      expression of CD80 and CD86 and cytokine secretion of LPS-activated DCs was also 
      quantified under Bortezomib. The ability of DCs to activate T cells was also 
      measured by the mixed lymphocyte reaction assay. Finally the effect of Bortezomib 
      on nuclear translocation of NF-kappaB was measured by EMSA. Bortezomib can inhibit 
      the proliferation of DCs in a dose- and time-dependent manner. It also blocked 
      the expression of co-receptors CD80 and CD86 and secretion of cytokines IL-12 and 
      TNF-alpha in DCs treated with LPS. Mixed lymphocyte reaction assay suggested 
      Bortezomib reduced the ability of DCs to activate T cells. Finally, we found 
      Bortezomib can inhibit the nuclear translocation of NF-kappaB in DCs. Our findings 
      indicated that Bortezomib blocked the functions of DCs in various aspects, and is 
      a potential drug candidate for GVHD.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Internal Medicine, First Hospital Affiliated to Suzhou University 
      China ; Department of Internal Medicine, Lianyungang First People's Hospital 
      China.
FAU - Liang, Yong
AU  - Liang Y
AD  - Institute of Biology and Medical Sciences to Suzhou University China ; Department 
      of Biological Treatment of Tumor Cells, Huai'an Second People's Hospital Huai'an, 
      China.
FAU - Zhang, Yanming
AU  - Zhang Y
AD  - Department of Internal Medicine, First Hospital Affiliated to Suzhou University 
      China ; Department of Biological Treatment of Tumor Cells, Huai'an Second 
      People's Hospital Huai'an, China.
FAU - Wu, Depei
AU  - Wu D
AD  - Department of Internal Medicine, First Hospital Affiliated to Suzhou University 
      China.
FAU - Liu, Haiyan
AU  - Liu H
AD  - Institute of Biology and Medical Sciences to Suzhou University China.
LA  - eng
PT  - Journal Article
DEP - 20150501
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (NF-kappa B)
RN  - 0 (Proteasome Inhibitors)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/*drug effects/metabolism
MH  - Bortezomib/*pharmacology
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Dendritic Cells/*drug effects
MH  - Humans
MH  - Male
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Proteasome Inhibitors/*pharmacology
PMC - PMC4503050
OTO - NOTNLM
OT  - Bortezomib
OT  - T cell activation
OT  - dendritic cells
OT  - graft versus-host disease
OT  - nuclear factor-kappaB
EDAT- 2015/07/21 06:00
MHDA- 2016/05/06 06:00
PMCR- 2015/05/01
CRDT- 2015/07/21 06:00
PHST- 2015/03/13 00:00 [received]
PHST- 2015/04/26 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 May 1;8(5):4857-62. eCollection 2015.